Are BRAF V600E and K-Ras Mutations Associated With Tumor Aggressiveness in Well-Differentiated Thyroid Cancer?
Articles > Article · 2019
Authors: Mutlu Unver, Özer MAKAY, Asli Kisim, Gulruh Emiroglu, Aysegul Aktas, Harika Atmaca, Timur KÖSE, Burcak Karaca, Yesim Ertan, Ruchan Uslu, Recep Gökhan İÇÖZ, Mahir Akyildiz, Mustafa Yilmaz
INTERNATIONAL SURGERY, Journal Indexed in SCI Expanded, International, 2019, vol 104, pp 99-106
DOI: 10.9738/intsurg-d-14-00145.1
Summary
Aim: Many clinical studies have shown an association between B-type rapidly growing fibrosarcoma kinase [BRAF(V600E)] mutation and aggressive clinicopathologic features, although some results from others are controversial. Besides, Kirsten rat sarcoma (K-Ras) mutations are more common in endemic iodine deficiency regions, as our country is. However, use of the biologic markers are questioned in clinical practice; they are beginning to be used for the management of patients with thyroid nodules and cancers. The aim of the present study was to evaluate the prevalence of the BRAF(V600E) mutation in tumor samples and its relationship to high-risk clinicopathologic features.